ArticleTrends in biotechnology2026
Comparison of technologies for manufacturing extracellular vesicles for therapeutic applications.
Article in Trends in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Targeting Gli1Stem cell reviews and reports · 2026Review
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- Seminiferous tubule-inspired coaxial bioprinting-derived extracellular vesicles restore Leydig cell steroidogenesis through modulation of Wnt4/β-catenin signaling.Journal of nanobiotechnology · 2026Article
- Nanomedicine novel strategies: deciphering the EV-metabolic axis as a natural nanocarrier network in lung cancer progression and cachexia.Journal of nanobiotechnology · 2026Review
- Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Extracellular vesicles (EVs) have gained significant attention as therapeutics, building from natural mechanisms of paracrine signaling. The field has evolved with substantial heterogeneity in methods to isolate and characterize EVs and new methods are needed to scale-up EV production for therapeutic use. In this study, we isolated EVs from four porcine donors of bone marrow-derived mesenchymal stromal cells (MSCs) via three different cell culture methods: standard tissue culture plates, a 3D printed perfusion bioreactor, and microcarriers in spinner flasks. We explored EV manufacturing yield, characteristics, and content via proteomics and RNAseq. The MSC donor and their cell culture method affected the yield of EVs produced, whereas the method of EV isolation dominated the clustering of protein and RNA contents. As a step towards therapeutic application, in vitro tubule formation and hypoxic cardiac spheroid contraction assays showed improvements in vasculogenesis and cardiac cell recovery, respectively, in the presence of EVs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.